Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

February 29, 2012

Study Completion Date

December 31, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Ketoconazole, Hydrocortisone and Dutasteride

"Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal"

Trial Locations (7)

Unknown

Sidney Kimmel Comprehensive Cancer Center at John Hopkins University, Baltimore

Oregon Health and Science University, Portland

MD Anderson Cancer Center, Houston

Sunnybrook and Women's College Health Sciences Center, Toronto

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

02214

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Sunnybrook Health Sciences Centre

OTHER

collaborator

Oregon Health and Science University

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT00673127 - Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter